AVEO Oncology (Nasdaq: AVEO) and its Japanese partner Astellas Pharma, have submitted kidney cancer drug candidate tivozanib to the U.S. Food and Drug Administration.
In advance of the submission, Cambridge, Mass.-based AVEO has been beefing up its staff, and in May, inked a deal for a new, larger headquarters.
If approved, it would be the first drug on the market developed by AVEO. The companies are seeking approval for treatment of patients with advanced renal cell carcinoma.